Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:physicist
|
| gptkbp:associated_with |
gptkb:healthcare_organization
clinical outcomes increased cell proliferation increased angiogenesis increased tumor aggressiveness specific clinical features adverse effects of treatment response to immunotherapy increased mutation burden specific clinical trials specific therapeutic strategies differentiation of tumor types increased risk of metastasis specific patient demographics specific survival outcomes specific therapeutic targets |
| gptkbp:caused_by |
uncontrolled cell growth
|
| gptkbp:clinical_trial |
ongoing research
|
| gptkbp:established |
gptkb:vemurafenib
gptkb:dabrafenib |
| gptkbp:genetic_diversity |
missense mutation
higher in younger patients |
| https://www.w3.org/2000/01/rdf-schema#label |
BRAF V600 E mutation
|
| gptkbp:impact |
MAPK signaling pathway
survival rates |
| gptkbp:influences |
treatment decisions
treatment outcomes |
| gptkbp:is_found_in |
tumor microenvironment
liquid biopsies tumor samples other cancers |
| gptkbp:is_linked_to |
disease progression
immune evasion mechanisms tumor heterogeneity specific biomarkers therapeutic resistance specific treatment regimens treatment efficacy studies resistance to certain therapies specific histological features treatment resistance mechanisms molecular profiling studies specific genetic profiles treatment monitoring strategies |
| gptkbp:is_noted_for |
gptkb:academic_journal
|
| gptkbp:is_often_used_in |
Caucasian populations
|
| gptkbp:is_popular_in |
found in approximately 40-60% of melanoma cases
|
| gptkbp:is_recognized_by |
gptkb:2002
genetic testing |
| gptkbp:is_studied_in |
clinical research
personalized medicine approaches |
| gptkbp:metabolism |
valine to glutamic acid at position 600
|
| gptkbp:promoter |
gptkb:BRAF
|
| gptkbp:recognizes |
PCR testing
|
| gptkbp:risk_factor |
poor prognosis
|
| gptkbp:screenings |
patients with advanced melanoma
|
| gptkbp:social_responsibility |
biopsy
|
| gptkbp:targets |
BRAF inhibitors
|
| gptkbp:treatment |
targeted therapy
|
| gptkbp:bfsParent |
gptkb:BEACON_trial
gptkb:dabrafenib |
| gptkbp:bfsLayer |
5
|